Lower resting cardiac output accelerates cerebral atrophy specifically in older adults carrying the APOE-e4 Alzheimer’s genetic risk factor, according to an 11-year longitudinal study published in Alzheimer’s & Dementia. The Vanderbilt Health research links subclinical heart function directly to faster brain volume loss.
While investigators have long understood that Alzheimer’s disease risk involves a mix of genetics and vascular health, the precise long-term trajectory connecting subclinical heart dysfunction to structural brain changes remained less clear. A longitudinal study conducted at Vanderbilt Health, involving researchers from the Vanderbilt Memory and Alzheimer’s Center (VMAC), set out to examine that exact mechanism over more than a decade. The investigation followed 756 participants over an 11-year period to determine whether reduced heart pump function could drive adverse brain health outcomes even among individuals without diagnosed cardiovascular disease, according to findings published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association.
Tracking Subclinical Cardiac Function in the Vanderbilt Cohort
The study leveraged data from the Vanderbilt Memory and Aging Project (VMAP), a specialized longitudinal cohort established to investigate vascular contributions to cognitive decline and brain aging. Launched in 2012, VMAP enrolled legacy participants ages 60 and older between 2012 and 2014 who were either cognitively unimpaired or met diagnostic criteria for mild cognitive decline. The study expanded in 2021 to enroll cognitively unimpaired adults ages 50 and older. The combined cohort ultimately comprised 756 adults aged 50 to 92, with an average age of 67, including 47 percent males and 81 percent non-Hispanic white participants, of whom 600 were cognitively unimpaired at baseline.
At enrollment, participants underwent comprehensive evaluations that featured fasting blood draws, physical examinations, clinical interviews with medication reviews, echocardiograms, and brain MRIs. These assessments were repeated across structured follow-up visits at 18 months, three years, five years, seven years, nine years, and 11 years. Researchers used echocardiography to quantify baseline cardiac output—the volume of blood pumped by the heart per minute—before deploying neuroimaging to track changes in gray matter volume and ventricular size over time, controlling for demographic variables in their statistical models.
APOE-e4 Status Modifies Neurodegeneration Risk
The analysis revealed a striking specificity when examining genetic risk profiles. Subclinical lower cardiac output was significantly associated with smaller brain volumes and faster ventricular expansion only in participants who carry the APOE-ε4 allele, a well-established genetic risk factor for late-onset Alzheimer’s disease. In non-carriers, the study found no meaningful relationship between heart output and brain atrophy rates.
The statistical interaction between baseline cardiac output and APOE-ε4 status proved robust, showing greater inferior lateral ventricle enlargement—a standard neuroimaging marker of brain tissue loss—specifically in carriers with lower baseline heart pump function. When evaluating regional brain structures, lower cardiac output at study entry correlated with smaller volumes across the entire brain as well as specifically within the temporal and occipital lobes among APOE-e4 carriers. Over the 11-year tracking period, that same lower baseline cardiac output successfully predicted greater temporal lobe atrophy, a critical brain region heavily implicated in Alzheimer’s pathology.
Precision Medicine and Upstream Cardiovascular Prevention
These findings position cardiac output as a potentially modifiable upstream risk factor in individuals who are already genetically predisposed to neurodegeneration.
“This study is among the first and largest to examine the impact of subclinical cardiac dysfunction on neurodegeneration over time, and among the first to evaluate how APOE-e4 status modifies these associations.”
Elizabeth Moore, MD, PhD, first author of the study, via Technology Networks
The research underscores the potential value of incorporating genetic risk data into cardiovascular screening protocols. Elizabeth Moore, MD, PhD, emphasized that the data points toward a precision medicine framework where periodic cardiac screening could be specifically tailored to protect brain health in individuals carrying genetic predispositions.
Methodological Caveats and Next Scientific Steps
Despite the strong statistical associations observed over the 11-year window, researchers and independent analysts urge caution when interpreting the results. Because the study is observational, it limits definitive causal inference regarding whether improving heart function directly halts brain atrophy. The study authors explicitly call for independent replication across separate cohorts to confirm how subclinical cardiac output interacts with genetic risk variants over extended timelines.
Related reading
